Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

AIMS/INTRODUCTION: Although the efficacy of teneligliptin, a highly selective dipeptidyl peptidase‐4 inhibitor, has been amply studied for the treatment of type 2 diabetes, no clinical trials of teneligliptin have been carried out in China. We evaluated the efficacy and safety of teneligliptin monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Linong, Ma, Jianhua, Lu, Weiping, Liu, Jingdong, Zeng, Jiao’e, Yang, Jialin, Li, Wei, Zhang, Xiuzhen, Xiao, Xinhua, Takayanagi, Gen, Wang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015819/
https://www.ncbi.nlm.nih.gov/pubmed/32810383
http://dx.doi.org/10.1111/jdi.13389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015819/
https://www.ncbi.nlm.nih.gov/pubmed/32810383
http://dx.doi.org/10.1111/jdi.13389

Ejemplares similares